Page last updated: 2024-12-06
propiram
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
propiram: RN given refers to parent cpd; synonym Bay 4503 refers to fumarate[1:1]; practically always used as fumarate in medicine; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 26216 |
| CHEMBL ID | 2110985 |
| CHEBI ID | 135140 |
| SCHEMBL ID | 26193 |
| MeSH ID | M0042579 |
Synonyms (41)
| Synonym |
|---|
| 52373-67-8 |
| wt6247u6px , |
| unii-wt6247u6px |
| propiramum |
| propiramo |
| propiram |
| 15686-91-6 |
| n-(1-methyl-2-piperidin-1-ylethyl)-n-pyridin-2-ylpropanamide |
| propanamide, n-(1-methyl-2-(1-piperidinyl)ethyl)-n-2-pyridinyl- |
| dea no. 9649 |
| propionamide, n-(1-methyl-2-piperidinoethyl)-n-2-pyridyl- |
| einecs 239-775-7 |
| propiramo [inn-spanish] |
| brn 0485057 |
| n-(1-methyl-2-(1-piperidinyl)ethyl)-n-2-pyridinylpropanamide |
| propiramum [inn-latin] |
| isopropiram |
| propiram [inn:ban] |
| pregnane-11,20-dione, 3,21-dihydroxy-, (3-alpha,5-alpha)- |
| (rs)-cis-n-(2-piperidinopropyl)-n-2-pyridylpropionamide |
| propionamide, n-(1-methyl-2-(1-piperidinyl)ethyl)-n-2-pyridyl- |
| propionamide, n-(2-piperidinopropyl)-n-2-pyridyl-, (rs)-(z)- |
| CHEBI:135140 |
| L004589 |
| n-(1-piperidin-1-ylpropan-2-yl)-n-pyridin-2-ylpropanamide |
| SCHEMBL26193 |
| n-(1-methyl-2-piperidinoethyl)-n-2-pyridylpropionamide |
| propiram [who-dd] |
| bay-4503 free base |
| ids-np-016(sect.2) |
| (+/-)-propiram |
| propiram [mi] |
| propiram [inn] |
| propanamide, n-[1-methyl-2-(1-piperidinyl)ethyl]-n-2-pyridinyl- |
| CHEMBL2110985 |
| ZBAFFZBKCMWUHM-UHFFFAOYSA-N |
| (.+/-.)-n-(1-methyl-2-piperidinoethyl)-n-2-pyridylpropionamide |
| n-(1-methyl-2-piperidinoethyl)-n-2-pyridinylpropionamide |
| propionamide, n-(1-methyl-2-piperidinoethyl)-n-2-pyridyl-, (.+/-.)- |
| DTXSID1023522 |
| Q7250338 |
Research Excerpts
Overview
Propiram is an orally administered opioid analgesic. It has partial morphine-like agonist and weak antagonist properties.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Propiram is an orally administered opioid analgesic with partial morphine-like agonist and weak antagonist properties. " | ( Propiram. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use as an analgesic. Brogden, RN; Goa, KL, 1993) | 3.17 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "Propiram bioavailability was determined in 10 healthy volunteers after a single role administration of 50 mg (base equivalent) of propiram fumarate in tablet or solution dosage from in a randomized crossover design." | ( Bioavailability of orally administered propiram fumarate in humans. Chung, M; Korduba, CA; Radwanski, E; Symchowicz, S; Veals, J, 1981) | 1.97 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propiram bioavailability was determined in 10 healthy volunteers after a single role administration of 50 mg (base equivalent) of propiram fumarate in tablet or solution dosage from in a randomized crossover design." | ( Bioavailability of orally administered propiram fumarate in humans. Chung, M; Korduba, CA; Radwanski, E; Symchowicz, S; Veals, J, 1981) | 1.97 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| pyridines | Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (75.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 38.11
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (38.11) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (50.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (40.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||